Email this article The state of cognitive functions in COVID-19 complicated by viral pneumonia in young and middle-aged patients in the period 2020–2022
- Authors: Kabysh S.S.1,2, Prokopenko S.V.1,3, Abdullaev M.B.1, Karpenkova A.D.1,2, Kuznetsova M.V.2, Golikova-Chereshkevich A.V.2, Frolova O.V.2
-
Affiliations:
- Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky
- Krasnoyarsk Interdistrict Clinical Hospital No. 20 named after I.S. Berzon
- Federal Scientific and Clinical Center of the Federal Medical and Biological Agency of the Russian Federation
- Issue: Vol LIV, No 4 (2022)
- Pages: 14-21
- Section: Original study arcticles
- URL: https://journals.rcsi.science/1027-4898/article/view/134186
- DOI: https://doi.org/10.17816/nb112460
- ID: 134186
Cite item
Open Access
Access granted
Subscription Access
Abstract
BACKGROUND. Currently, the study of the cognitive sphere in COVID-19 is an urgent problem.
AIM. To determine the presence of cognitive dysfunction using valid scales MoCA, FAB, clock drawing test and their subscales in patients in the acute period of coronavirus infection, to compare the data of cognitive impairment in different epidemiological waves.
MATERIAL AND METHODS. Two groups of subjects were included in the present study. Groups No. 1 and No. 2 are patients infected with COVID-19 in the acute period, complicated by pneumonia. Group No. 1 was hospitalized in the period December 2020 — March 2021. Group No. 2 was hospitalized in the period November 2021 — January 2022. To study the neuropsychological status, the neuropsychological scales MoCA, FAB, the clock drawing test and their subscales were used. Screening for anxiety and depression and depression was performed using the valid HADS scale. Quantitative data on the normality of the distribution of the sample was tested using the Shapiro–Wilk test. The Mann–Whitney test was used to compare unrelated groups. Quantitative data are presented as median and interquartile range — Me [P25; P75]. Differences were considered statistically significant at p <0.05.
RESULTS. Statistically significant differences were found in the acute period of coronavirus infection complicated by pneumonia and cognitive impairment in both group No. 1 and group No. 2, respectively. In group No. 1 (observation period from December 2020 to March 2021), cognitive impairments were more severe than in group No. 2 (observation period from November 2021 to January 2022). When comparing the subscales of the MoCA test of groups No. 1 and No. 2 upon admission to the hospital, and at discharge in group No. 1, the results of MoCA testing were worse than in group No. 2 according to subscales: attention, speech, memory, indicators were statistically significant (p <0.05). According to the FAB data, in group No. 1, the indicators on admission to the hospital and at discharge were also worse than in group No. 2, highly significant differences were according to the data: fluency of speech, dynamic praxis, simple and complicated choice reaction, grasping reflex study (p < 0.001). Anxiety and depression were not found in the study groups.
CONCLUSION. With the help of such valid scales as: the clock drawing test, MoCA, FAB and their subscales, the presence of cognitive dysfunction in young and middle-aged patients at different time intervals of observation was proved; in the first group, the violations were more severe than in the group No. 2.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Sergey S. Kabysh
Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky; Krasnoyarsk Interdistrict Clinical Hospital No. 20 named after I.S. Berzon
Author for correspondence.
Email: sergioowl@yandex.ru
ORCID iD: 0000-0002-9029-4553
SPIN-code: 5926-3024
Postgraduate Student, Depart. of Nervous Diseases with a Postgraduate Education Course
Russian Federation, Krasnoyarsk; KrasnoyarskSemyon V. Prokopenko
Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky; Federal Scientific and Clinical Center of the Federal Medical and Biological Agency of the Russian Federation
Email: s.v.proc.58@mail.ru
ORCID iD: 0000-0002-4778-2586
M.D., D. Sci. (Med.), Prof., Head of Depart., Depart. of the Nervous Diseases with a Postgraduate Education Course
Russian Federation, Krasnoyarsk; KrasnoyarskMurad B. Abdullaev
Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky
Email: murad25abdullaev@gmail.com
ORCID iD: 0000-0002-2673-4999
Resident, Depart. of Nervous Diseases with a Postgraduate Education Course
Russian Federation, KrasnoyarskAlena D. Karpenkova
Krasnoyarsk State Medical University named after Professor V.F. Voyno-Yasenetsky; Krasnoyarsk Interdistrict Clinical Hospital No. 20 named after I.S. Berzon
Email: pobejdaujay@mail.ru
ORCID iD: 0000-0002-9058-8818
Postgraduate Student, Depart. of Nervous Diseases with a Postgraduate Education Course
Russian Federation, Krasnoyarsk; KrasnoyarskMary V. Kuznetsova
Krasnoyarsk Interdistrict Clinical Hospital No. 20 named after I.S. Berzon
Email: irem35106@gmail.com
ORCID iD: 0000-0002-9909-5796
M.D., Neurologist
Russian Federation, KrasnoyarskAlexandra V. Golikova-Chereshkevich
Krasnoyarsk Interdistrict Clinical Hospital No. 20 named after I.S. Berzon
Email: 89658908573@mail.ru
ORCID iD: 0000-0002-4748-7907
Clinical Psychologist
Russian Federation, KrasnoyarskOlga V. Frolova
Krasnoyarsk Interdistrict Clinical Hospital No. 20 named after I.S. Berzon
Email: Frolova_olga86@mail.ru
ORCID iD: 0000-0001-8807-2540
M.D., Neurologist
Russian Federation, KrasnoyarskReferences
- Mahboubi MM, Karvandi MS, Maafi P et al. Neurological complications associated with COVID-19; molecular mechanisms and therapeutic approaches. Rev Med Virol. 2022;32(6):e2334. doi: 10.1002/rmv.2334.
- Maury A, Lyoubi A, Peiffer-Smadja N et al. Neurological manifestations associated with SARS-CoV-2 and other coronaviruses: A narrative review for clinicians. Rev Neurol (Paris). 2021;177(1–2):51-64. doi: 10.1016/j.neurol.2020.10.001. PMID: 33446327. PMCID: PMC7832485.
- Newcombe VFJ, Dangayach NS, Sonneville R. Neurological complications of COVID-19. Intensive Care Med. 2021;47:1021–1023. doi: 10.1007/s00134-021-06439-6.
- Zhou JLC, Sun Y, Huang W et al. Cognitive disorders associated with hospitalization of COVID-19: Results from an observational cohort study. Brain Behav Immun. 2021;91:383–392. doi: 10.1016/j.bbi.2020.10.019.
- Ollila H, Pihlaja R, Koskinen S et al. Long-term cognitive functioning is impaired in ICU-treated COVID-19 patients: A comprehensive controlled neuropsychological study. Crit Care. 2022;26:223. doi: 10.1186/s13054-022-04092-z.
- Miskowiak KW, Johnsen S, Sattler SM et al. Cognitive impairments four months after COVID-19 hospital discharge: Pattern, severity and association with illness variables. Eur Neuropsychopharmacol. 2021;46:39–48. doi: 10.1016/j.euroneuro.2021.03.019.
- Huang C, Huang L, Wang Y et al. 6-Month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 2021;397(10270):220–232. doi: 10.1016/S0140-6736(20)32656-8.
- Raman B, Cassar MP, Tunnicliffe EM et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. eClinicalMedicine. 2021;31:100683. doi: 10.1016/j.eclinm.2020.100683.
- Brutto OHD, Wu S, Mera RM et al. Cognitive decline among individuals with history of mild symptomatic SARS-CoV-2 infection: A longitudinal prospective study nested to a population cohort. Eur J Neurol. 2021;28(10):3245–3253. doi: 10.1111/ene.14775.
- Stavem K, Einvik G, Tholin B et al. Cognitive function in non-hospitalized patients 8–13 months after acute COVID-19 infection: A cohort study in Norway. PLoS One. 2022;17(8):e0273352. doi: 10.1371/journal.pone.0273352.
- Houben S, Bonnechère B. The impact of COVID-19 infection on cognitive function and the implication for rehabilitation: A systematic review and meta-analysis. Int J Environ Res Public Health. 2022;19(13):7748. doi: 10.3390/ijerph19137748.
- Poletti S, Palladini M, Mazza MG et al. Long-term consequences of COVID-19 on cognitive functioning up to 6 months after discharge: Role of depression and impact on quality of life. Eur Arch Psychiatry Clin Neurosci. 2022;272:773–782. doi: 10.1007/s00406-021-01346-9.
- Crivelli L, Palmer K, Calandri I et al. Changes in cognitive functioning after COVID-19: A systematic review and meta-ana-lysis. Alzheimer’s Dement. 2022;4(10):e2130645. doi: 10.1002/alz.12644.
- Alemanno F, Houdayer E, Parma A et al. COVID-19 cognitive deficits after respiratory assistance in the subacute phase: A COVID-rehabilitation unit experience. PLoS One. 2021;16(2):e0246590. doi: 10.1371/journal.pone.0246590.
